newsfilter
← Earnings
Earnings Releases·

LivaNova — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue rose 9.9% to $393.1 million; adjusted diluted EPS increased to $1.23 from $1.11, while GAAP diluted EPS declined to $0.11 from $0.49.
  • Full-year 2026 guidance was raised: revenue growth to 9–10% (up 100 bps) and adjusted diluted EPS to $4.40–$4.50 (up $0.10 midpoint), with free cash flow guidance unchanged at $140–$160 million.
  • Both Cardiopulmonary (+10.9%) and Neuromodulation (+11.1%) segments drove growth, supported by new CPT codes for hypoglossal nerve stimulation and published 36-month CORE-VNS study results showing a 76% median seizure reduction.
  • Balance sheet remains strong with $563.5 million in cash and cash equivalents; management cites robust global demand and operational capacity expansion for oxygenators as key drivers.
Company
LIVANOVA PLC
Sector
Healthcare
Industry
Medical Devices